One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their weight in 36 weeks, according to early-stage trial results on Friday, boosting the drugmaker's shares.

Novo Nordisk shares rose sharply after the Danish pharmaceutical giant said an experimental weight-loss shot helped patients lose 22% of their bodyweight in a clinical trial.

Novo Nordisk shares jumped on Friday as the Danish drugmaker said an experimental drug was able to reduce weight by as much as 22%.

Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 products, by mimicking a hormone in the body that provides a satiated feeling and curbs hunger, but adds a different hormone in the pancreas.

Novo Nordisk on Friday announced early-stage trial results for its amycretin obesity drug for subcutaneous injection, saying people with obesity or overweight treated with the drug achieved a 22% weight loss after 36 weeks.

On Friday, however, Novo Nordisk announced top-line results in yet another trial. While the results don't initially sound as good as those in the trials cited above, however, the speed at which they were achieved has investors cheering, and Novo Nordisk stock is up 7.7% through 10:50 a.m. Friday morning.

Novo Nordisk was slammed by a U.K. trade group for not disclosing payments to health and patient groups, according to a draft report obtained by STAT.

Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for its amycretin weight-loss drug.

Novo Nordisk is opening a new front in its fight against sickle cell disease, inking a deal with IMMvention Therapeutix to co-develop oral treatments for the red blood cell disorder and other chronic conditions.

Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated prices for Ozempic, Wegovy, and Rybelsus will be. In Medicare's negotiations for 2026, the new prices achieved an average of 22% savings.

A new weight loss drug from Novo Nordisk helped patients lose a large amount of weight, providing a boost for Novo in the competitive field.

Good news about an experimental weight-loss shot sent shares in Ozempic maker Novo Nordisk soaring, making it once again Europe's most-valuable listed company. A pullback in the Danish drug maker's shares had meant it recently ceded that title to French luxury conglomerate LVMH.